hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06324890, orgStudyIdInfo id: 20240225, briefTitle: PET-CT Imaging Features of Meibomian Glands, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-31, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Zhongnan Hospital, class: OTHER, descriptionModule briefSummary: Analysis the results of Dry eye analysis results and PET-CT imaging comprehensively, conditionsModule conditions: MGD-Meibomian Gland Dysfunction, conditions: Positron-Emission Tomography, conditions: Dry Eye, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: RETROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, outcomesModule primaryOutcomes measure: Lacrimal river height, primaryOutcomes measure: Tear break-up time, primaryOutcomes measure: Tear-film lipid layer thickness, primaryOutcomes measure: Meibomian glands two-dimensional digital infrared images, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zhongnan Hospital of Wuhan University, status: RECRUITING, city: Wuhan, state: Hubei, zip: 430071, country: China, contacts name: Min Ke, Doctor, role: CONTACT, phone: +86-18672395959, email: keminyk@163.com, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False
protocolSection identificationModule nctId: NCT06324877, orgStudyIdInfo id: HREC/24/QCHQ/106030, briefTitle: Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside, acronym: ATNAD, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-10-30, completionDateStruct date: 2025-10-30, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: The University of Queensland, class: OTHER, descriptionModule briefSummary: Study design: Single arm open-label clinical trial in ataxia-telangiectasia to test the effects of nicotinamide riboside on ataxia scales, immune function, and neurofilament light chain. Study population: 6-10 patients with Ataxia-Telangiectasia. Dose: Nicotinamide riboside 25 mg/kg/day in 3 equal divided doses.Primary endpoint: Scales for assessment and rating of ataxia (SARA), and International Cooperative Ataxia Rating Scale (ICARS). Improvement of at least ½ standard deviation in key clinical scales which includes either; a) significant improvement in total combined scores from the SARA and ICARS scales, and /or b) significant improvements any aspects of the SARA and ICARS scales individually, especially pertaining to; Postural and gait improvements, Improved syllable speed and articulation, Improved fine motor skills.Secondary endpoints: Serum analysis of neurofilament light chain (Nfl), Type 1 Interferon (INFs) epigenetic signature, conditionsModule conditions: Ataxia Telangiectasia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: 1. Primary objective: Single arm open-label clinical trial in ataxia-telangiectasia to test the effects of nicotinamide riboside on ataxia scales, immune function, and neurofilament light chain.2. Secondary objectives:   * Determine to what extent the beneficial effects ongoing of NR on NFl translate to clinical efficacy in patients with A-T.   * Type 1 Interferon (INFs) epigenetic signature specifically the cGAS-STING pathway., primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Nicotinamide riboside, outcomesModule primaryOutcomes measure: Scales for assessment and rating of ataxia, primaryOutcomes measure: International Cooperative Ataxia Rating Scale, secondaryOutcomes measure: Serum analysis of neurofilament light chain, secondaryOutcomes measure: Type 1 Interferon epigenetic signature, otherOutcomes measure: Quality of Life Measures, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Queensland Children's Hospital, city: Brisbane, state: Queensland, zip: 4101, country: Australia, contacts name: David Coman, MBBS FRACP, role: CONTACT, phone: +610730681111, email: david.coman@health.qld.gov.au, geoPoint lat: -27.46794, lon: 153.02809, hasResults: False
protocolSection identificationModule nctId: NCT06324864, orgStudyIdInfo id: 2024-00212, briefTitle: START NOW Adapted: Culturally Adapted Version of START NOW, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-13, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-03, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Prof. Christina Stadler, class: NETWORK, descriptionModule briefSummary: The goal of this clinical trial is to test the effectiveness of the culturally adapted skills-training START NOW in youth migrant populations. The main question it aims to answer is: Is the culturally adapted skills training START NOW more effective than treatment as usual (TAU) in reducing mental health problems in migrants? Participants will be randomly assigned to the intervention group receiving the skills training START NOW Adapted or the control group receiving TAU. Researchers will compare both groups to see if START NOW Adapted is more effective than TAU in reducing mental health problems in migrants., conditionsModule conditions: Depression, conditions: Depression/Anxiety, conditions: Anxiety, conditions: Adolescent, conditions: Emotion Recognition, conditions: Mental Health, conditions: Resilience,Psychological, conditions: Refugee Health, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: START NOW Adapted, outcomesModule primaryOutcomes measure: Change from baseline in symptoms of depression and anxiety at the end of the intervention, primaryOutcomes measure: Change from baseline in symptoms of depression and anxiety at follow-up, secondaryOutcomes measure: Change from baseline in self-reported perceived stress at follow-up, secondaryOutcomes measure: Change from baseline in self-reported social-ecological resilience at the end of the intervention, secondaryOutcomes measure: Change from baseline in self-reported perceived stress at the end of the intervention, secondaryOutcomes measure: Change from baseline in self-reported social-ecological resilience at follow-up, secondaryOutcomes measure: Change from baseline in facial emotion recognition at the end of the intervention, secondaryOutcomes measure: Change from baseline in facial emotion recognition at follow-up, eligibilityModule sex: ALL, minimumAge: 15 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: University Psychiatric Clinics Basel, status: RECRUITING, city: Basel, state: Basel-Stadt, zip: 4002, country: Switzerland, contacts name: Donja Brunner, PhD, role: CONTACT, phone: +410613258031, email: donja.brunner@unibas.ch, contacts name: Janine Bacher, MSc, role: CONTACT, phone: +410613258048, email: janine.bacher@upk.ch, contacts name: Donja Brunner, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 47.55839, lon: 7.57327, hasResults: False
protocolSection identificationModule nctId: NCT06324851, orgStudyIdInfo id: DROVZOEFFIPREP, briefTitle: The Use of Drospirenone/Estetrol, Nomegestrol Acetate/Estradiol and Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2023-08-01, completionDateStruct date: 2024-03-01, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: University of Palermo, class: OTHER, collaborators name: University of Roma La Sapienza, descriptionModule briefSummary: The presence of a thin endometrium plays an important role in enabling the best conditions for hysteroscopic surgery. Recently, for this purpose, many studies have evaluated the effect of preoperative administration of a variety of drugs. We explored the efficacy of random started 14-day administration of Drospirenone/Estetrol or Nomegestrol Acetate/Estradiol or Ethinylestradiol/Dienogest, in rapid preparation of endometrium for hysteroscopic polypectomy., conditionsModule conditions: Endometrial Polyp, conditions: Endometrial Diseases, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ACTUAL, armsInterventionsModule interventions name: Drospirenone / Estetrol, interventions name: Nomegestrol Acetate / Estradiol, interventions name: Ethinylestradiol / Dienogest, outcomesModule primaryOutcomes measure: Quality of endometrial preparation, eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Andrea Etrusco, city: Palermo, zip: 90123, country: Italy, geoPoint lat: 38.13205, lon: 13.33561, locations facility: Marco Monti, city: Rome, zip: 00161, country: Italy, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06324825, orgStudyIdInfo id: 2022CR64, briefTitle: Fuzheng Nizeng Formula for Chronic Atrophic Gastritis With Low-grade Intraepithelial Neoplasia, a Multicenter Randomized Controlled Trial, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-10-24, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Peking University First Hospital, class: OTHER, descriptionModule briefSummary: Fuzheng Nizeng Formula (FZNZ) is derived from the classic formula Liujunzi Decoction. Former pilot study found that FZNZ promoted the recovery of gastric atrophy and relieve the relative symptoms. This study is to evaluate its efficacy for chronic atrophic gastritis with low-grade intraepithelial neoplasia, compared with positive control Molduodan granule., conditionsModule conditions: Atrophic Gastritis With Low-grade Intraepithelial Neoplasia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 144, type: ESTIMATED, armsInterventionsModule interventions name: Fuzhegn Nizeng Decoction, interventions name: Moluodan granules, outcomesModule primaryOutcomes measure: Recovery rate of Low-grade Intraepithelial Neoplasia, secondaryOutcomes measure: 7-point Global Overall Symptom Scale, secondaryOutcomes measure: Adverse event rate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking University First Hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100034, country: China, contacts name: Xuezhi Zhang, Doctor, role: CONTACT, phone: +861083572634, email: zhang.xuezhi@263.net, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06324812, orgStudyIdInfo id: SSGJ-611-PED-AD-Ib/II-01, briefTitle: Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-08, completionDateStruct date: 2024-08, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The primary objective of the study was to evaluate the safety and pharmacokinetic of 611 in Chinese children and adolescents with moderate to severe atopic dermatitis., conditionsModule conditions: Dermatitis, Atopic, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 104, type: ESTIMATED, armsInterventionsModule interventions name: Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611), outcomesModule primaryOutcomes measure: Adverse events (AEs), measurement of vital signs，physical examination，electrocardiogram and laboratory tests at each visit., primaryOutcomes measure: Minimum concentration (Cmin), secondaryOutcomes measure: Number of Participants with Eczema Area and Severity Index (EASI) - 75 Response (>= 75% Improvement in Score From Baseline), secondaryOutcomes measure: Number of Participants with Investigator's Global Assessment (IGA) Score of "0" or "1" and Improvement From Baseline of Greater Than or Equal to (>=) 2 Points, secondaryOutcomes measure: Number of Participants with Eczema Area and Severity Index (EASI) - 50 Response (>= 50% Improvement in Score From Baseline), secondaryOutcomes measure: Number of Participants with Eczema Area and Severity Index (EASI) - 90 Response (>= 90% Improvement in Score From Baseline), secondaryOutcomes measure: Number of Participants Who Achieved >=4 Points/ >=3 Points With Improvement From Baseline in Weekly Average of Pruritus Numerical Rating Scale (NRS) Score From Baseline, secondaryOutcomes measure: Percentage Change From Baseline in EASI Score, secondaryOutcomes measure: Change From Baseline in Percent Body Surface Area (BSA) of AD Involvement, secondaryOutcomes measure: Change From Baseline in Weekly Average of Pruritus NRS, secondaryOutcomes measure: Change From Baseline in Children's Dermatology Life Quality Index (CDLQI), secondaryOutcomes measure: Change From Baseline in Patient Oriented Eczema Measure (POEM), eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06324786, orgStudyIdInfo id: 2024 IBMT NF, briefTitle: Brain Mechanisms of Reducing Polysubstance Use, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-01, primaryCompletionDateStruct date: 2026-08-31, completionDateStruct date: 2026-08-31, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Arizona State University, class: OTHER, descriptionModule briefSummary: The proposed study will test whether neurofeedback (NF) could optimize integrative body-mind training (IBMT) practice., conditionsModule conditions: Multiple Drug Use, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: mindfulness or/and active/sham neurofeedback, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 35, type: ESTIMATED, armsInterventionsModule interventions name: IBMT, interventions name: NF, outcomesModule primaryOutcomes measure: Intervention effects on brain function using Functional Magnetic Resonance Imaging (fMRI), primaryOutcomes measure: Intervention effects on brain white matter using fMRI, primaryOutcomes measure: Intervention effects on brain grey matter using fMRI, secondaryOutcomes measure: Intervention effects on addiction behavior using substance use questionnaires in PhenX Toolkit, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: YiYuan Tang, status: RECRUITING, city: Phoenix, state: Arizona, zip: 85004, country: United States, contacts name: YiYuan Tang, role: CONTACT, phone: 480-790-3577, email: yiyuan@asu.edu, geoPoint lat: 33.44838, lon: -112.07404, hasResults: False
protocolSection identificationModule nctId: NCT06324773, orgStudyIdInfo id: 9867, briefTitle: Prevalence of Postpartum Family Planning and Its Association With Spousal Joint Decision-Making in Family Planning, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-06-20, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Aga Khan University, class: OTHER, descriptionModule briefSummary: This community-based cross-sectional study investigates the prevalence of postpartum family planning (PPFP) uptake and its association with joint spousal family planning decision-making among married women in rural Sindh, Pakistan. The study, conducted in Thatta District with a population of approximately 0.98 million people, addresses sociodemographic challenges including high fertility rates, maternal and newborn mortality, and low contemporary contraception use. Targeting married women aged 18-49 who gave birth within the past year, the research utilizes data from the Global Network's Maternal and Newborn Health Registry. Data collection involves a pretested questionnaire administered by trained female data collectors. Statistical analysis includes descriptive statistics and logistic regression using STATA 17. The study aims to fill knowledge gaps regarding factors influencing PPFP uptake, particularly the role of joint decision-making in family planning. Findings could inform targeted interventions to enhance maternal and child health, contribute to existing knowledge, and guide policymakers and healthcare providers in addressing the unmet need for family planning in rural Pakistan., conditionsModule conditions: Postpartum Family Planning, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 510, type: ESTIMATED, outcomesModule primaryOutcomes measure: Prevalence of Postpartum Family Planning Uptake, primaryOutcomes measure: Frequency of spousal joint decision making for uptake of postpartum family planning, primaryOutcomes measure: Comparison between spousal joint decision making is using postpartum family planning method and non-users., eligibilityModule sex: ALL, minimumAge: 15 Years, maximumAge: 49 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06324760, orgStudyIdInfo id: LIPOICSPI2018, briefTitle: Alpha-lipoic Acid Combined With B Vitamins Shows Promise for Treating Restless Legs Syndrome, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-03-04, primaryCompletionDateStruct date: 2021-06-02, completionDateStruct date: 2021-06-02, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Uriach Consumer Healthcare, class: INDUSTRY, descriptionModule briefSummary: Investigating Tiobec® 400's efficacy in alleviating Restless Legs Syndrome symptoms sheds light on promising therapeutic avenues., conditionsModule conditions: Restless Legs Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 20, type: ACTUAL, armsInterventionsModule interventions name: Alpha-lipoic acid combined with B vitamins, outcomesModule primaryOutcomes measure: Measure the subjective RLS symptoms of the participants through the IRLSSG rating scale (IRLS), secondaryOutcomes measure: Anthropometric parameters of the patients., secondaryOutcomes measure: Patients' body measurements, secondaryOutcomes measure: Measurements of patient anatomy, secondaryOutcomes measure: Patients' body characteristics., secondaryOutcomes measure: Measurements of patient anatomy., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Medical Center Teknon, city: Barcelona, zip: 08017, country: Spain, geoPoint lat: 41.38879, lon: 2.15899, hasResults: False
protocolSection identificationModule nctId: NCT06324747, orgStudyIdInfo id: 23-046, briefTitle: Soft Tissue Stability in Immediate Implant Placement Using (VST) Versus Conventional Flap in Type II Extraction Sockets, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-10-23, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2024-12-01, studyFirstPostDateStruct date: 2024-03-22, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: British University In Egypt, class: OTHER, descriptionModule briefSummary: This study compare between the vestibular socket therapy (VST) and the traditional mucoperiosteal flap reflection in immediate implant placement in type II extraction socket in the esthetic zone.The technique of vestibular socket therapy (VST), introduced by Elaskry, enables the placement of implants immediately while simultaneously rehabilitating the entire socket, resulting in excellent esthetic and functional outcomes that meet the expectations of patients. VST involves socket augmentation through a minimally invasive vestibular access incision, eliminating the need for the traditional mucoperiosteal flap reflection, regardless of the extent of socket compromise., conditionsModule conditions: Badly Broken Tooth in a Socket Type II Eligible to be Replaced by Immediate Implant, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Two equal parallel groups with a 1:1 allocation ratio to receive either vestibular socket therapy (test group) or to be treated with conventional mucoperiosteal flap (control group)., primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Due to the differences in techniques, the operating surgeon can not be blinded to the procedure, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 16, type: ACTUAL, armsInterventionsModule interventions name: Vestibular socket therapy, interventions name: conventional full thickness flap, outcomesModule primaryOutcomes measure: Soft Tissue Stability, secondaryOutcomes measure: Bone Regeneration, otherOutcomes measure: Pink Esthetic Score (PES), eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: The British university in Egypt, city: Cairo, state: New Cairo, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False